Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin Diseases AND Plaque Psoriasis AND Adalimumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Skin Diseases AND Plaque Psoriasis AND Adalimumab. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-003287-37 Sponsor Protocol Number: EMR200588-002 Start Date*: 2016-03-15
    Sponsor Name:Merck KGaA
    Full Title: A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-Approved Humira® in subjects with moderate to severe chro...
    Medical condition: moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-000943-17 Sponsor Protocol Number: NL54557.091.15 Start Date*: 2016-02-11
    Sponsor Name:Radboudumc
    Full Title: Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial.
    Medical condition: Adult Patients diagnosed psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10015581 Exacerbation of psoriasis LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037155 Psoriasis and similar disorders LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037156 Psoriasis flare-up LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001066-17 Sponsor Protocol Number: CNTO1959PSO2001 Start Date*: 2012-04-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X...
    Medical condition: Moderate to Severe Plaque-type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003022-40 Sponsor Protocol Number: UKM14_0008 Start Date*: 2015-03-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003392-22 Sponsor Protocol Number: PS0008 Start Date*: 2018-03-19
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety o...
    Medical condition: Moderate to severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-006015-29 Sponsor Protocol Number: ADA-IJZ-3001 Start Date*: 2022-08-04
    Sponsor Name:Mylan Pharmaceuticals Inc., a Viatris Company
    Full Title: A Multicenter, Randomized, Blinded, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Betwe...
    Medical condition: Moderate to Severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003275-36 Sponsor Protocol Number: M13-674 Start Date*: 2014-04-29
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic P...
    Medical condition: Nail psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10028703 Nail psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000632-15 Sponsor Protocol Number: CHS-1420-02 Start Date*: 2015-09-25
    Sponsor Name:Coherus BioSciences, Inc.
    Full Title: A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira® in Subjects With Chronic Plaque Psoriasis (PsOsim)
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) IT (Completed) SK (Completed) EE (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003623-65 Sponsor Protocol Number: 1311.30 Start Date*: 2016-05-17
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: BI 655066/ABBV-066 (risankizumab) versus adalimumab in a randomized, double blind, parallel group trial in moderate to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatm...
    Medical condition: psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FI (Completed) PT (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002254-20 Sponsor Protocol Number: 1297.9 Start Date*: 2017-08-04
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: VOLTAIRE-X: Pharmacokinetics, safety, immunogenicity and efficacy of BI 695501 versus Humira® in patients with moderate to severe chronic plaque psoriasis: a randomized, double-blind, parallel-arm,...
    Medical condition: moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004918-18 Sponsor Protocol Number: OPTIMAP Start Date*: 2014-02-03
    Sponsor Name:Academic Medical Center
    Full Title: Optimising adalimumab treatment in psoriasis with concomitant methotrexate.
    Medical condition: psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013072-52 Sponsor Protocol Number: M04-717 Start Date*: 2011-05-09
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicentre, Randomised, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plaque Psoriasis (Ps)
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed) Outside EU/EEA NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001593-15 Sponsor Protocol Number: B15-884 Start Date*: 2016-08-08
    Sponsor Name:Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
    Full Title: A Multi-center, Randomized, Double blind, Prospective Study to Evaluate the Efficacy and Safety of high induction doses of adalimumab in moderate to severe psoriasis patients. The DEEP study.
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000695-19 Sponsor Protocol Number: SB5-4001 Start Date*: 2022-07-22
    Sponsor Name:Samsung Bioepis Co., Ltd
    Full Title: A Phase IV, Randomised, Double-blind, Parallel-group, Multiple-dose, Active Comparator, Multicentre Clinical Study to Evaluate the Pharmacokonetics, Efficacy, Safety, and Immunogenicity of SB5 Vers...
    Medical condition: Moderate to severe plaque psioriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000815-15 Sponsor Protocol Number: BOS-1168-WEI-0080-I Start Date*: 2011-08-02
    Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen
    Full Title: BOSTRIP (Investigator Initiated Trial) (Biomarkers of systemic treatment response in Psoriasis) Differential analysis of metabolomic profiles in patients with chronic plaque psoriasis underg...
    Medical condition: Psoriasis is a chronic hyperproliferative and inflammatory skin disease with its major subtype, chronic plaque-type psoriasis, affecting approximately 2% of individuals in Western populations. It m...
    Disease:
    Population Age: Elderly Gender:
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004614-26 Sponsor Protocol Number: ONS-3010-002 Start Date*: 2016-07-25
    Sponsor Name:Oncobiologics Limited
    Full Title: A Randomized, Double-Blind, Multicenter, Equivalence Study of ONS-3010 and Humira® for the Treatment of Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PL (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000719-15 Sponsor Protocol Number: CNTO1959PSO3001 Start Date*: 2014-10-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001751-76 Sponsor Protocol Number: 911401 Start Date*: 2015-08-26
    Sponsor Name:Momenta Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of M923 (a Proposed Adalimumab Biosimilar) and Humira® in Subjects with Moderate to Severe Chr...
    Medical condition: Chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) DE (Completed) LV (Completed) EE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000537-12 Sponsor Protocol Number: 20120263 Start Date*: 2013-09-25
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000720-18 Sponsor Protocol Number: CNTO1959PSO3002 Start Date*: 2015-02-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 16:57:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA